Found 36 clinical trials
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.
, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.
- 0 views
- 20 Jul, 2021
- 29 locations
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
-cancer agents in participants with advanced malignancies.
- 12 views
- 25 Jul, 2021
- 5 locations
Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer
. More advanced radiotherapy techniques, that result in fewer toxicities, means that we are now able to combine new anti-cancer agents into standard treatment. Targeting the tumour early in this
- 5 views
- 24 Jan, 2021
- 1 location
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
- 400 views
- 05 Jul, 2021
- 62 locations
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to
- 64 views
- 25 Jul, 2021
- 25 locations
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity
- 0 views
- 24 May, 2021
- 25 locations
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
Treatment with polysorbate 80-solved Docetaxel (Taxotere) is hampered by the requirement to co-administer steroids. Chronic (intermittent) steroids are negatively impacting bone health and have well known immunosuppressive effects. Despite steroid premedication, polysorbate 80-solved Docetaxel (Taxotere) results in occasional infusion reactions due to the solvent polysorbate 80. Docetaxel micellar is a …
- 0 views
- 15 Jun, 2021
- 3 locations
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
- 84 views
- 14 May, 2021
- 55 locations
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive
- 0 views
- 08 Jul, 2021
- 70 locations
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care) vs. secondary (current …
- 7 views
- 31 Jan, 2021
- 20 locations